Literature DB >> 6381595

The role of I-A/E molecules in B lymphocyte activation. I. Inhibition of lipopolysaccharide-induced responses by monoclonal antibodies.

S Forsgren, G Pobor, A Coutinho, M Pierres.   

Abstract

A panel of 22 different monoclonal antibodies, including specificities against various antigenic clusters of I-A and I-E molecules, were probed over a wide range of concentrations for their ability to inhibit lipopolysaccharide-induced B lymphocyte proliferation and maturation to immunoglobulin-secreting plaque-forming cells (PFC). Most antibodies were competent to inhibit up to 80 to 100% of the response of appropriate target cells, although having little or no effect on irrelevant spleen cell cultures. Mixtures of either anti-I-A or anti-I-E specificities were more efficient inhibitors than individual antibodies, as shown by the average concentrations required for 50% inhibition (30 and 300 ng/ml, respectively). The selective role of I-A/E molecules in B cell activation was demonstrated by the failure of anti-K antibodies of the same isotype, bound in comparable amounts to target cells, to modulate B cell responses in parallel cultures. Fc receptor-mediated inhibitory effects were further excluded by equivalent inhibition obtained with anti-I-A antibodies of the IgM class. Anti-I-A/E antibodies appear to inhibit the inductive phase of B cell responses, as suggested by limiting dilution experiments performed in the presence of 50% inhibitory concentrations of antibodies: 50% of the control number of reactive clones were found to respond, but those that escaped inhibition developed to control sizes of progenies producing PFC.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6381595

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  15 in total

1.  Morphine suppresses MHC-II expression on circulating B lymphocytes via activation of the HPA.

Authors:  Alexandria L Nugent; Richard A Houghtling; Barbara M Bayer
Journal:  J Neuroimmune Pharmacol       Date:  2010-05-04       Impact factor: 4.147

2.  Idiotypic and anti-idiotypic B-B cell interaction is controlled by major histocompatibility complex-restricted regulation.

Authors:  S Bitoh; S Fujimoto; H Yamamoto
Journal:  Immunology       Date:  1989-04       Impact factor: 7.397

3.  Activation of genetically major histocompatibility complex (MHC) class II-deficient B lymphocytes.

Authors:  A Durandy; M Mangeney; C Griscelli; M Forveille; F Le Deist; A Fischer
Journal:  J Clin Immunol       Date:  1989-03       Impact factor: 8.317

4.  Activation-specific interactions among B-lymphocyte plasma membrane proteins.

Authors:  M G Goodman; R L Wolfert
Journal:  Immunol Res       Date:  1986       Impact factor: 2.829

5.  Stimulation of B-cell proliferation by membrane-associated molecules from activated T cells.

Authors:  A A Brian
Journal:  Proc Natl Acad Sci U S A       Date:  1988-01       Impact factor: 11.205

6.  Abnormal differentiation of immunoregulatory T-lymphocyte subpopulations in the major histocompatibility complex (MHC) class II antigen deficiency syndrome.

Authors:  L T Clement; J V Giorgi; S Plaeger-Marshall; A Haas; E R Stiehm; A M Martin
Journal:  J Clin Immunol       Date:  1988-11       Impact factor: 8.317

Review 7.  Cellular signalling mechanisms in B lymphocytes.

Authors:  W Cushley; M M Harnett
Journal:  Biochem J       Date:  1993-06-01       Impact factor: 3.857

8.  Induction of B cell apoptosis by TH0, but not TH2, CD4+ T cells.

Authors:  X He; W Zhong; J J Goronzy; C M Weyand
Journal:  J Clin Invest       Date:  1995-02       Impact factor: 14.808

9.  Anti-class II MHC antibodies prevent and treat EAE without APC depletion.

Authors:  R M Smith; A Morgan; D C Wraith
Journal:  Immunology       Date:  1994-09       Impact factor: 7.397

10.  Lipopolysaccharide-induced IgM production is not suppressed by antigen receptor ligation in B cells from some autoimmune strains of mice.

Authors:  C C Anderson; R Rahimpour; N R Sinclair
Journal:  Immunol Res       Date:  1994       Impact factor: 2.829

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.